AstraZeneca first quarter revenue straight down 11 percent to $7,349 million Initial quarter results reflect difficult revenue picture. Pipeline strengthened by Amgen collaboration, the contract to obtain Ardea Biosciences and positive CHMP opinion for FORXIGA in Europe. Income for the first one fourth was $7,349 million, down 11 % at constant exchange prices . – Lack of exclusivity on many crucial brands accounted for 8 %age factors of the income decline, including the acknowledgement of a $223 million returns reserve against US trade inventories of Seroquel IR pursuing generic launches by the end of March 2012.

sexual stimulationdue to thised cuew

AstraZeneca recruits individuals for KODIAC Stage III trial in opioid-induced constipation AstraZeneca today announced that research centers over the U.S. Are recruiting sufferers for a clinical research to examine whether an investigational medication is effective and safe in treating opioid-induced constipation . The scholarly study, known as KODIAC, is certainly a Phase III medical trial examining an investigational medication in sufferers experiencing constipation because of opioid use, that is a potential side-effect of prescription opioid discomfort medicines.